---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-396065"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2026-09-21T11:10:39+00:00"
generated_at: "2026-09-21T11:15:19.040992+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alkermes ALKS 7290 shows positive Phase 1b ADHD data; AISRS cuts 14–19 pts

## Summary
- ALKS 7290 (OX2R agonist) improved ADHD symptoms: median AISRS reductions of 14.0 (20 mg) and 19.0 (50 mg) at day 14.
- CGI-S median reductions of 1.0 (20 mg) and 2.0 (50 mg) at day 14; shift from markedly/moderately ill to mildly ill.
- Generally well tolerated; no serious TEAEs; most common mild events: insomnia, pollakiuria, dizziness, change in sustained attention.
- Phase 2 study (NCT07755410) enrolling ~312 adults with ADHD; first dose Sept 2026; data expected 2027.
- First orexin 2 receptor agonist to show clinically meaningful ADHD improvements; supports broader orexin portfolio.

## SEC filing metadata
- accession: 0001193125-26-396065
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2026-09-21T11:10:39+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/0001193125-26-396065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-396065
- JSON: https://secwatch.observer/filing/0001193125-26-396065.json
- Plain text: https://secwatch.observer/filing/0001193125-26-396065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.